|Articles|February 1, 2002
Drug companies defend discount programs in the wake of GAO scrutiny
Washington, D.C.-Drug manufacturers are revamping their recentlyannounced discount programs in order to gainsay a recent survey from theU.S. General Accounting Office, which reported that the discount card programsmight not have the impact and savings that they had intended.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
Cancer survival fell and deaths rose during first two years of COVID-19
4
TrumpRx launches; some experts question its long-term value
5





















